Identification of a novel germline MET mutation in dogs

Animal Genetics

Volumn 37, Issue 3, 2006, Pages 248-252

  Liao, A T ^a   McMahon, M ^a   London, C A ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Dog; Germline; MET; Mutation

Indexed keywords

SCATTER FACTOR RECEPTOR;

ANIMAL; ANIMAL DISEASE; ARTICLE; CELL MOTION; CELL STRAIN 3T3; CHEMISTRY; DOG; DOG DISEASE; GENETICS; MOUSE; MUTATION; NEOPLASM; POINT MUTATION; PROTEIN TERTIARY STRUCTURE;

ANIMALS; CELL MOVEMENT; DOG DISEASES; DOGS; GERM-LINE MUTATION; MICE; NEOPLASMS; NIH 3T3 CELLS; POINT MUTATION; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-MET;

CANIS FAMILIARIS;

EID: 33744495087     PISSN: 02689146     EISSN: 13652052     Source Type: Journal    
DOI: 10.1111/j.1365-2052.2006.01415.x     Document Type: Article

References (22)

1. Birchmeier C., Birchmeier W., Gherardi E. Vande Woude G.F. 2003 Met, metastasis, motility and more. Nature Reviews. Molecular Cell Biology 4, 915 25.
2. Bottaro D.P., Rubin J.S., Faletto D.L., Chan A.M., Kmiecik T.E., Vande Woude G.F. Aaronson S.A. 1991 Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 251, 802 4.
3. Christensen J.G., Burrows J. Salgia R. 2005 c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Letters 225, 1 26.
4. Downing S., Chien M.B., Kass P.H., Moore P.E. London C.A. 2002 Prevalence and importance of internal tandem duplications in exons 11 and 12 of c-kit in mast cell tumors of dogs. American Journal of Veterinary Research 63, 1718 23.
5. Gandino L., Longati P., Medico E., Prat M. Comoglio P.M. 1994 Phosphorylation of serine 985 negatively regulates the hepatocyte growth factor receptor kinase. Journal of Biological Chemistry 269, 1815 20.
6. Giordano S., Ponzetto C., Di Renzo M.F., Cooper C.S. Comoglio P.M. 1989 Tyrosine kinase receptor indistinguishable from the c-met protein. Nature 339, 155 6.
7. Graveel C., Su Y., Koeman J., Wang L.M., Tessarollo L., Fiscella M., Birchmeier C., Swiatek P., Bronson R. Vande Woude G. 2004 Activating Met mutations produce unique tumor profiles in mice with selective duplication of the mutant allele. Proceedings of the National Academy of Sciences of the United States of America 101, 17198 203.
8. Jeffers M., Fiscella M., Webb C.P., Anver M., Koochekpour S. Vande Woude G.F. 1998 The mutationally activated Met receptor mediates motility and metastasis. Proceedings of the National Academy of Sciences of the United States of America 95, 14417 22.
9. Jiang W., Hiscox S., Matsumoto K. Nakamura T. 1999 Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer. Critical Reviews in Oncology/Hematology 29, 209 48.
10. Jiang W.G., Martin T.A., Parr C., Davies G., Matsumoto K. Nakamura T. 2005 Hepatocyte growth factor, its receptor, and their potential value in cancer therapies. Critical Reviews in Oncology/Hematology 53, 35 69.
11. Lee J.H., Han S.U., Cho H., Jennings B., Gerrard B., Dean M., Schmidt L., Zbar B. Vande Woude G.F. 2000 A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene 19, 4947 53.
12. Liao A.T., McMahon M. London C.A. 2005 Characterization, expression and function of c-Met in canine spontaneous cancers. Veterinary and Comparative Oncology 3, 61 72.
13. Lingaas F., Comstock K.E., Kirkness E.F. et al. 2003 A mutation in the canine BHD gene is associated with hereditary multifocal renal cystadenocarcinoma and nodular dermatofibrosis in the German Shepherd dog. Human Molecular Genetics 12, 3043 53.
14. Ma P.C., Kijima T., Maulik G., Fox E.A., Sattler M., Griffin J.D., Johnson B.E. Salgia R. 2003a c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Research 63, 6272 81.
15. Ma P.C., Maulik G., Christensen J. Salgia R. 2003b c-Met: structure, functions and potential for therapeutic inhibition. Cancer and Metastasis Reviews 22, 309 25.
16. Ma P.C., Jagadeeswaran R., Jagadeesh S. et al. 2005 Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Research 65, 1479 88.
17. Peschard P., Fournier T.M., Lamorte L., Naujokas M.A., Band H., Langdon W.Y. Park M. 2001 Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. Molecular Cell 8, 995 1004.
18. Schmidt L., Duh F.M., Chen F. et al. 1997 Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nature Genetics 16, 68 73.
19. Schmidt L., Junker K., Weirich G. et al. 1998 Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene. Cancer Research 58, 1719 22.
20. Schmidt L., Junker K., Nakaigawa N. et al. 1999 Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 18, 2343 50.
21. Shelly S., Chien M.B., Yip B., Kent M.S., Theon A.P., McCallan J.L. London C.A. 2005 Exon 15 BRAF mutations are uncommon in canine oral malignant melanomas. Mammalian Genome 16, 211 7.
22. Zaffaroni D., Spinola M., Galvan A. et al. 2005 Met proto-oncogene juxtamembrane rare variations in mouse and humans: differential effects of Arg and Cys alleles on mouse lung tumorigenesis. Oncogene 24, 1084 90.